Our Leadership Team
Back
Stacey Ayres, Ph.D.
Vice President, Regulatory Strategy
Stacey A. Ayres, PhD, is an accomplished regulatory strategist with more than two decades of pharmaceutical industry experience and nearly two decades specializing in the 505(b)(2) drug approval pathway. As Vice President, Regulatory Strategy, Dr. Ayres leads regulatory strategy for complex drug development programs across a broad range of therapeutic areas, including small molecules, biologics, and drug-device combination products.
Dr. Ayres has extensive experience defining scientifically sound, streamlined pathways to regulatory approval, integrating clinical, nonclinical, chemistry, manufacturing, and controls (CMC), device, and regulatory considerations to address complex development challenges and manage regulatory risk. Her approach emphasizes pragmatic strategies that improve development efficiency, leverage existing knowledge and regulatory precedent, and support meaningful product differentiation.
She has extensive experience engaging with FDA on 505(b)(2) and other complex drug development programs, including numerous pre-IND, End-of-Phase 2, pre-NDA, and other regulatory interactions. A particular area of expertise is developing creative and pragmatic 505(b)(2) strategies that leverage existing information, regulatory precedent, scientific bridging, and appropriate reliance pathways to define efficient development programs and the evidence necessary to support approval. Her experience also encompasses INDs, NDAs, and ANDAs, as well as the development of regulatory positions, briefing packages, and scientific justifications supporting FDA interactions throughout the product lifecycle.
Dr. Ayres also has extensive experience developing strategies to leverage regulatory designations, incentives, and exclusivity opportunities, including Orphan Drug Designation, Qualified Infectious Disease Product designation, Fast Track and Breakthrough Therapy Designations, Rare Pediatric Disease Designation, and priority review voucher programs. Her experience includes orphan drug strategies involving clinical superiority, major contribution to patient care, and orphan subsets, as well as Citizen Petitions and Suitability Petitions.
Complementing her regulatory strategy work, Dr. Ayres has experience in product ideation, product selection, portfolio strategy, and integrated feasibility assessment for 505(b)(2) opportunities. She integrates scientific, medical, regulatory, development, and commercial considerations to assess product viability and identify efficient development strategies, with a focus on managing regulatory risk, leveraging available regulatory opportunities, and supporting commercial differentiation.